Examkin

Question

Difficulty: HardPreventive Care and Screening

A 56-year-old woman comes to the clinic for a routine health maintenance visit. She was diagnosed with severe plaque psoriasis one year ago and is currently maintained on adalimumab and topical corticosteroids, with excellent control of her skin disease. Her past medical history is otherwise notable for hypertension. She is planning a trip to a rural area in South America in two months and wants to ensure all her preventive care and travel vaccinations are up to date. Her social history includes a 10 pack-year smoking history, but she quit 20 years ago. Preventive care records indicate her last colonoscopy at age 51 was normal, cervical cancer screening with primary HPV testing at age 54 was negative, and a screening mammogram at age 55 was normal. She received the recombinant zoster vaccine series at age 51, a tetanus and diphtheria (Td) booster 3 years ago, and both the seasonal influenza and updated COVID-19 vaccines last month. She has never received a pneumococcal or yellow fever vaccine. Which of the following is the most appropriate next step in her preventive care?

  1. A
    Administer the live-attenuated yellow fever vaccine
  2. Administer the 20-valent pneumococcal conjugate vaccineAnswer
  3. C
    Order a screening dual-energy x-ray absorptiometry scan
  4. D
    Order a low-dose chest computed tomography scan
  5. E
    Schedule a screening colonoscopy

Answer

Administer the 20-valent pneumococcal conjugate vaccine
The correct answer is administering the 20-valent pneumococcal conjugate vaccine. Adults aged 19 to 64 years with an immunocompromising condition, including those receiving immunosuppressive medications such as tumor necrosis factor (TNF) inhibitors (e.g., adalimumab), are at increased risk for invasive pneumococcal disease. Current guidelines recommend these patients receive either a single dose of the 20-valent pneumococcal conjugate vaccine (PCV20) or a dose of the 15-valent pneumococcal conjugate vaccine (PCV15) followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Since this patient has never received a pneumococcal vaccine, administering PCV20 is the correct next step in her preventive care.

Step-by-Step Solution

1
Identify the patient's risk profile and current medications.
The patient is a 56-year-old woman on adalimumab (a TNF-alpha inhibitor) for psoriasis. She is effectively immunocompromised.
Current medications heavily influence both indications and contraindications for preventive care and travel medicine.
2
Evaluate the request for travel vaccinations against her medication profile.
Although traveling to a yellow fever endemic area, yellow fever is a live-attenuated vaccine, which is contraindicated in patients on biologic response modifiers.
Administering a live vaccine to an immunocompromised patient carries a high risk of disseminated infection.
3
Assess age and condition-specific vaccine indications based on her immunocompromised state.
Immunocompromised adults aged 19-64 years require pneumococcal vaccination. Since she has never received one, administering PCV20 is indicated.
Patients on immunosuppressive therapy are at elevated risk for invasive pneumococcal disease.
4
Review routine age-based cancer and bone screening guidelines.
She does not meet criteria for lung cancer screening (insufficient pack-years, quit too long ago) or early DEXA scanning, and her next colonoscopy is not due for 5 years.
Rules out unnecessary testing and confirms that standard age-based screenings are appropriately up to date.

Key Concept

Preventive care in immunocompromised patients (e.g., those on TNF inhibitors) requires targeted vaccinations such as the pneumococcal vaccine prior to age 65, while strictly avoiding live-attenuated vaccines.
Rate this question

Topics

Preventive Care and Screening

More questions from this topic